Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q3 FY21 results · Oct–Dec 2020
Marksans Pharma reported revenue from operations of ₹358.36 crore (up 24.6% from Q3 FY20) and net profit of ₹58.94 crore (up 99.4% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 358.36 | 287.65 | +24.6% | 356.47 | +0.5% |
| Other income | (3.17) | 0.03 | Turned loss | 3.67 | Turned loss |
| Total income | 355.19 | 287.68 | +23.5% | 360.14 | −1.4% |
| Profit before tax | 77.64 | 38.34 | +102.5% | 65.90 | +17.8% |
| Net profit for the period | 58.94 | 29.56 | +99.4% | 50.73 | +16.2% |
| EPS, basic (₹) | 1.42 | 0.71 | +100.0% | 1.21 | +17.4% |
| Net margin (%) | 16.4 | 10.3 | 14.2 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 168.46 | 116.88 | +44.1% | 137.55 | +22.5% |
| Other income | 6.24 | 0.01 | 892x | 12.96 | −51.8% |
| Total income | 174.70 | 116.89 | +49.5% | 150.51 | +16.1% |
| Profit before tax | 35.99 | 16.12 | +123.3% | 31.01 | +16.1% |
| Net profit for the period | 29.10 | 12.97 | +124.3% | 23.53 | +23.7% |
| EPS, basic (₹) | 0.71 | 0.32 | +121.9% | 0.57 | +24.6% |
| Net margin (%) | 17.3 | 11.1 | 17.1 |
Consolidated
- Filed with BSE
- 08 Feb 2021, 16:45 IST
- Board meeting
- 08 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Feb 2021, 16:45 IST
- Board meeting
- 08 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE